We observed a significant trend in increasing exposure-efficacy relationships across the low-, intermediate-, and high-probability groups with the VDZ-CDST.
← all excerpts
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
1
—
—